

agreements, written or oral, express or implied between the parties concerning the subject matter of the investigation.” 19 CFR 210.21(b)(1).

Consistent with Commission Rule 210.21(b)(1), redacted versions of a patent license agreement and a settlement agreement between Rovi and Comcast were attached to the motion as Exhibits 1 and 2 and the unredacted agreements were filed separately under a confidential header. The moving parties submit that the agreements resolve the allegations of infringement against Comcast in the investigation. Motion at 1. In further compliance with Commission Rule 210.21(b)(1), the motion contains a statement that there are no other agreements, written or oral, express or implied between the parties concerning the subject matter of the investigation. *Id.* at 2. The movants submit that termination is in the interest of the public and administrative economy. *Id.* at 3.

Pursuant to Commission Rule 210.50(b)(2), the Commission finds no evidence that terminating this investigation will adversely affect the public health and welfare, competitive conditions in the U.S. economy, the production of like or directly competitive articles in the United States, or U.S. customers. 19 CFR 210.50(b)(2). Moreover, the public interest generally favors settlement to avoid needless litigation and to conserve public resources. *See, e.g., Certain Semiconductor Devices, Products Containing the Same, and Components Thereof (II)*, Inv. No. 337-TA-1177, Order No. 5 at 2 (Nov. 25,

2019), *unreviewed by* Comm’n Notice (Dec. 20, 2019).

Accordingly, the Commission finds that the joint motion for termination satisfies Commission Rules 210.21(a)(2) and (b)(1) (19 CFR 210.21(a)(2), (b)(1)) and that termination of the investigation is not contrary to the public interest.

Accordingly, the Commission grants the joint motion to terminate the investigation in its entirety based on settlement. The investigation is terminated.

The Commission vote for this determination took place on November 30, 2020.

The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in part 210 of the Commission’s Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: November 30, 2020.

Katherine Hiner,

Supervisory Attorney.

[FR Doc. 2020-26685 Filed 12-3-20; 8:45 am]

BILLING CODE 7020-02-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-751]

Importer of Controlled Substances Application: Janssen Pharmaceuticals Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Janssen Pharmaceuticals Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplemental Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before January 4, 2021. Such persons may also file a written request for a hearing on the application on or before January 4, 2021.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrisette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrisette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrisette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on November 11, 2020, Janssen Pharmaceuticals Inc., 1440 Olympic Drive, Athens, Georgia 30601-1645, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
|-------------------------------|-----------|----------|
| Thebaine | 9333 | II |
| Poppy Straw Concentrate | 9670 | II |
| Tapentadol | 9780 | II |

The company plans to import intermediate forms of Tapentadol (9780) and Thebaine (9333) for further manufacturing prior to distribution to its customers. The company plans to import Poppy Straw Concentrate (9670) to bulk manufacture other controlled substances. No other activity for these drug codes is authorized for this registration.

Approval of permit applications will occur only when the registrant’s business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-

approved finished dosage forms for commercial sale.

William T. McDermott,

Assistant Administrator.

[FR Doc. 2020-26653 Filed 12-3-20; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Notice of Lodging of Proposed Consent Decree Under the

Comprehensive Environmental Response, Compensation and Liability Act

On November 27, 2020, the Department of Justice lodged a proposed Consent Decree with the United States District Court for the District of New Jersey in the lawsuit entitled *United States et al. v. Unimatic Manufacturing, Corp. et al.*, Civil Action No. 2:20-cv-17284.

The proposed Consent Decree would resolve claims the United States, New Jersey Department of Environmental Protection (“NJDEP”) and the Administrator of the New Jersey Spill Compensation Fund have brought pursuant to Section 107 of the Comprehensive Environmental Response, Compensation, and Liability